

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WUXI BIOLOGICS (CAYMAN) INC.**

**藥明生物技術有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2269)**

## **OBITUARY**

### **MOURNING THE PASSING OF DR. NING ZHAO**

It is with deep sadness that the board (the “**Board**”) of directors (the “**Director(s)**”) of WuXi Biologics (Cayman) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) shares the news that Dr. Ning Zhao (“**Dr. Zhao**”), co-founder of the Company, non-executive Director, member of the remuneration committee of the Company and member of the environmental, social and governance committee of the Company, passed away on May 16, 2023.

Dr. Zhao was an extraordinary scientist, business leader and philanthropist with unwavering commitment to improving human health. She obtained her bachelor’s degree in chemistry from Peking University, and her doctoral degree in organic chemistry from Columbia University, and then began her industry career with rising responsibilities in research and management with leading organizations. As one of the Company’s co-founders and an invaluable member of the Board, Dr. Zhao contributed immensely to the Company’s growth and success and played an instrumental role in shaping the Company into what it is today.

During the long and relentless battle against cancer, her strong sense of purpose led to her tireless global philanthropic efforts to support cancer research and foster future leaders so new treatments and cures will benefit patients around the world for years to come.

Dr. Zhao will be deeply missed. Her vision and spirit will live on through all of us, and guide the Company forward towards a future where “every drug can be made, and every disease can be treated”.

Following the passing away of Dr. Zhao, the Board comprises eight Directors, including two executive Directors, three non-executive Directors and three independent non-executive Directors, and does not have a Director of a different gender. As such, the Company is unable to meet the requirement under Rule 13.92 of the Rules (the “**Listing Rules**”) Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), where the Stock Exchange will not consider diversity to be achieved for a single gender board.

The Company will endeavor to make the necessary appointment in order to fulfill the requirements of the Listing Rules above and fill the vacancy as soon as practicable, and in any event within three months from the date of passing of Dr. Zhao. The Company will make further announcement(s) as and when appropriate.

By order of the Board  
**WuXi Biologics (Cayman) Inc.**  
**Dr. Ge Li**  
*Chairman*

Hong Kong, May 17, 2023

*As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III and Mr. Jackson Peter Tai as independent non-executive Directors.*

\* *For identification purpose only*